Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alaric DeArment

Reporter

Alaric has covered health care and the biopharma industry for over 12 years. He started out covering retail pharmacy for Drug Store News and shifted to writing for the pharma audience at BioPharm Insight, where highlights of his coverage included breaking stories about the early growing pains of CAR-T cell therapy development. Most recently he covered the biopharma beat at MedCity News. His professional interests include cell and gene therapies, hematology-oncology and the intersection of biopharma with artificial intelligence and machine learning. A native of Seattle, he holds a bachelor degree in journalism from Ball State University and also lived in China for three years. He is currently based in Brooklyn. Outside of work, Alaric’s interests include reading, coin collecting, travel and languages.

Latest From Alaric DeArment

What Will JAK Inhibitor Safety Jitters Mean For Drug Sales?

Together with a similar delay for AbbVie’s Rinvoq, the delays appear to stem from a study that raised concerns about the class. But the potential sales impact is less clear.

Commercial Research and Development Strategies

Scholar Rock Sees Phase III Path For SMA Drug

While the drug may be well-positioned for registrational development, some important caveats remain after mixed data in Phase II study cohorts.

Research & Development Research and Development Strategies

Biden Infrastructure Plan Offers Biopharma R&D Carrot, Tax Stick

Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.

Policy & Regulation Tax

Adolescent Results Put Pfizer/BioNTech Ahead Of COVID Vaccine Pack, For Now

An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.

Coronavirus COVID-19 Business Strategies

Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner

Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.

Research & Development Research and Development Strategies

Wave’s Huntington Drugs Wipe Out As Trials Run Aground

The company now turns to its next-generation Huntington drug, WVE-003.

Research & Development Research and Development Strategies
See All
UsernamePublicRestriction

Register